PA5-27436

antibody from Invitrogen Antibodies

Targeting: AIF1 AIF-1, Em:AF129756.17, IBA1, IRT-1

Provider product page for PA5-27436

Western blot

Immunoprecipitation

Antibody data

Antibody Data
Antigen structure
References [38]
Comments [0]
Validations
Western blot [7]
Immunocytochemistry [2]
Immunohistochemistry [8]
Flow cytometry [2]
Other assay [39]

Submit

Product number: PA5-27436 - Provider product page
Provider: Invitrogen Antibodies
Product name: IBA1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Predicted reactivity: Bovine, Pig, Rhesus Monkey (>80% identity)
Reactivity: Human, Mouse, Rat
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

AIF1 protein structure - PA5-27436 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Iba1 using Various whole cell extracts (30 µg). Samples were loaded onto a 15% SDS-PAGE gel and probed with an Iba1 polyclonal antibody (Product # PA5-27436) at a dilution of 1:2500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Iba1 using Mouse tissue extracts (50 µg). Samples were loaded onto a 15% SDS-PAGE gel and probed with an Iba1 polyclonal antibody (Product # PA5-27436) at a dilution of 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of IBA1 was performed by separating 50 µg of various tissue extracts by 15% SDS-PAGE. Proteins were transferred to a membrane and probed with a IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of IBA1 was performed by separating 30 µg of various whole cell extracts by 15% SDS-PAGE. Proteins were transferred to a membrane and probed with a IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:5000 and a HRP-conjugated anti-rabbit IgG secondary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using IBA1 Polyclonal Antibody (Product # PA5-27436). Various whole cell extracts (30 µg) were separated by 15% SDS-PAGE, and the membrane was blotted with IBA1 Polyclonal Antibody (Product # PA5-27436) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockout of IBA1 was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, AssayID CRISPR741364_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of IBA1 was performed by loading 30 µg of THP-1 wild type (Lane 1), THP-1 CAS9 (Lane 2), THP-1 IBA1 KO (Lane 3) whole cell extracts. The blot was probed with Anti-IBA1 Polyclonal Antibody (Product # PA5-27436) using 1:2000 dilution and Goat anti-Rabbit IgG (H+L), Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036). Loss of signal upon CRISPR mediated knockout (KO) using the LentiArray™ CRISPR product line confirms that antibody is specific to IBA1.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot was performed using Anti-IBA1 Polyclonal Antibody (Product # PA5-27436) and a 17 kDa band corresponding to IBA1 was observed across U-937, U-937 treated with Retinoic Acid and THP-1. Whole Cell Extract-WCL (30 µg lysate) of U-937 (Lane 1), U-937 treated with Retinoic Acid (10 µM for 24 hours) (Lane 2), THP-1 (Lane 3), A-431 (Lane 4), HeLa (Lane 5) and MCF7 (Lane 6), were electrophoresed using NuPAGE™ 12% Bis-Tris Protein Gel (Product # NP0342BOX). Resolved proteins were then transferred onto a Nitrocellulose membrane (Product # IB23002) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:2000 dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036,1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of IBA1 was performed in paraffin-embedded rat brain tissue using IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Frozen) analysis of IBA1 was performed in frozen sectioned E13.5 Rat brain tissue using IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:250 (Green). Red: beta Tubulin 3/ TUJ1, a mature neuron marker, stained by beta Tubulin 3/ TUJ1 antibody diluted at 1:500. Blue: Fluoroshield with DAPI.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of IBA1 was performed in paraffin-embedded mouse thymus gland tissue using IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of IBA1 was performed in paraffin-embedded mouse brain tissue using IBA1 Polyclonal Antibody (Product # PA5-27436) at a dilution of 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IBA1 Polyclonal Antibody detects Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded mouse brain. Iba1 stained by IBA1 Polyclonal Antibody (Product # PA5-27436) diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IBA1 Polyclonal Antibody detects Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded mouse cerebellum. Iba1 stained by IBA1 Polyclonal Antibody (Product # PA5-27436) diluted at 1:1,000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IBA1 Polyclonal Antibody detects Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded rat brain. Iba1 stained by IBA1 Polyclonal Antibody (Product # PA5-27436) diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IBA1 Polyclonal Antibody detects Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded rat cerebellum. Iba1 stained by IBA1 Polyclonal Antibody (Product # PA5-27436) diluted at 1:1,000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunofluorescence of a radial section of a human cochlear duct showing the distribution of IBA1 cells. In the spiral prominence, some IBA1 cells almost reach the endolymph. Scanning electron microscopy shows a free cell transitioning a cell border in the human cochlea (upper inset). Reissner's membrane (RM) may also contain macrophages (lower inset). In the SV, IBA1 cells are mostly found in the middle layer close to the blood vessels. No IBA1 cells can be observed in the organ of Corti in this section. I-IV; fibrocytes.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of Iba1 was performed in K562 whole cell extracts using 5 µg of IBA1 Polyclonal Antibody (Product # PA5-27436). Samples were transferred to a membrane and probed with IBA1 Polyclonal Antibody as a primary antibody and an HRP-conjugated anti-Rabbit IgG was used as a secondary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Glial Markers. Immunochemical analysis of the frontal cortex ( A ) and hippocampus ( B ) processed for anti-glial fibrillary acidic protein (GFAP). To investigate more than GFAP protein on the same blot, both membranes of the frontal cortex and hippocampus were stripped and incubated with anti-GAPDH antibody (loading control). Control images are re-used for illustrative purposes. The densitometric analysis of bands is expressed as the ratio between the optical density of protein and reference protein (GADPH) where the value for LZRs of different ages is set as 1. Blots are representative of one of three separate experiments. ( C ) Sections of the frontal cortex of LZRs and OZRs of different weeks of 12-, 16-, and 20-weeks age processed for the immunohistochemistry against the GFAP. V; IV: fifth and sixth layers of the frontal cortex. Magnification 40X. Calibration bar: 25 mum. ( D ) Sections of the hippocampus (CA1 subfield) of LZRs and OZRs of different weeks of age processed for the immunohistochemistry against ionized calcium-binding adaptor molecule 1 (Iba-1) to detect microglial cells O: stratum oriens ; P: pyramidal neurons; R: stratum radiatum. Calibration bar: 25 mum. ( E ) Sections of the hippocampus (CA1 subfield) and ( F ) dentate gyrus of 20 weeks-old LZRs and OZRs processed for double immunohistochemistry against Iba-1 (Alexa Fluore 594) and GFAP (Alexa Fluore 488). DAPI was used to counterstain nuclei. O: stratum oriens ; P: pyramidal neurons; R: stratu

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Effects of quinovic acid against amyloid-beta-induced neuroinflammation. (a) Western blot results of Iba-1, GFAP, p-JNK, IL-1 beta , and p-NF- kappa B in the experimental groups, with respective bar graphs. (b) Representative immunofluorescence images of Iba-1 and GFAP in the cortex and hippocampus (DG) of the experimental groups, with respective bar graphs. Scalebar = 50 mu m. The values of western blot results were normalized to 1. beta -Actin was used as a loading control; the densities were measured in arbitrary unit (A.U.). Data are presented as mean +- SEM. * P < 0.05 compared with the control group. # P < 0.05 compared with the A beta -treated group. Abbreviations: Iba-1: ionized calcium-binding adaptor molecule 1; GFAP: glial fibrillary acidic protein; p-JNK: phosphorylated c-Jun N-terminal kinase; IL-1 beta : interleukin 1 beta; p-NF- kappa B: phospho-nuclear factor-kappa B.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Experimental T. cruzi infection induces spinal cord astrocytes (A-E) and microglial (F-J) activation. Gfap and Iba1 mRNA expression was determined in control noninfected and infected mice 7-28 days p.i. every 7 days by RT-qPCR (A, F , respectively). At day 7 p.i. (peak of Gfap and Iba1 mRNA expression), Western blot analysis of the spinal cord was performed to confirm GFAP (B) and Iba-1 (G) expression. Next, 7-day spinal cord samples were stained with antibodies for astrocytes (C-E) and microglia (H-J) (GFAP and Iba-1, respectively; green) and regular nucleus (DAPI, blue) detection. Representative immunostainings of the spinal cord of control noninfected and infected mice are shown in panels (C, D, H, I) , respectively (20x magnification, scale bar 75 mum with zoom). Panels (E, J) show the percentage of GFAP and Iba-1 fluorescence intensity in each experimental group, respectively. Results are presented as mean +- SEM of six (A, B, F, G) or four mice (E, J) per group per experiment and are representative of two separate experiments. * p < 0.05 compared to control noninfected mice (one-way ANOVA followed by Tukey's posttest).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Targeting spinal cord NFkappaB with PDTC intrathecal treatment inhibits T. cruzi -induced glial activation and hyperalgesia as well as targeting glial cells with alpha-aminoadipate and minocycline reduced spinal cord NFkappaB activation. Panels (A-C) show RT-qPCR data for Gfap and Iba1 mRNA expression and mechanical and thermal hyperalgesia after vehicle and PDTC treatments (300 mug) at the 7th day p.i. Panel (D) presents blood parasitemia at the 7th day p.i. 7 h after the treatments. Panel (E) presents survival rates during the experimental protocol. The effects of targeting spinal cord glial cells with alpha-aminoadipate and minocycline upon NFkappaB activation at the 7th day p.i. 7 h after the treatments are presented in panel (F) . Representative immunostainings of triple immunofluorescence (DAPI/pNFkappaB p65/GFAP and DAPI/pNFkappaB p65/Iba-1) of the spinal cord of control noninfected and infected mice are shown in (G) (20x magnification, scale bar 50 mum). 3-D images with zoom demonstrating pNFkappaB p65 staining surrounded by GFAP or Iba-1 are shown in inserts. Panels H and I demonstrate the fluorescence intensity (%) of GFAP and pNFkappaB p65, and Iba-1, and pNFkappaB p65, respectively. Results are presented as mean +- SEM of six (A-F) or four mice (G-I) per group per experiment and are representative of two separate experiments. * p < 0.05 compared to control noninfected mice; # p < 0.05 compared to infected mice treated with vehicle (one-way ANOVA followed

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 4D9 antibody modulates TREM 2 functions within the brain Schematic outlining study design and timeline of intraperitoneal injections of either isotype control of 4D9 antibody in 6-month-old APP-NL-G-F and age-matched WT mice. Immunohistochemical costainings of TREM2 (magenta) and IBA1 (green) microglia in the cortex of isotype control and 4D9-injected WT and APP-NL-G-F mice. Side panel shows images from each staining at a larger magnification indicated by the dotted white boxes. Scale bar = 10 mum; scale bar (inset) = 2.5 mum. Quantification of cortical TREM2 stainings shown in (B). Two-way ANOVA, Tukey''s multiple comparison test (genotype effect: F 1,23 = 70.63, P 0.9999; P (WT isotype vs APP isotype) = 0.02; P (WT 4D9 vs APP 4D9) < 0.0001; P (APP isotype vs APP 4D9) = 0.0001; n.s., not significant. Quantification of cortical IBA1 staining shown in B. Two-way ANOVA, Tukey''s multiple comparison test (genotype effect: F 1,21 = 215.4, P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Extracellular Tau aggregates internalization, induced by alpha-linolenic acid in microglia . Internalization of hTau40 recombinant Tau in Iba-1 positive microglia. (a) Cells were incubated with hTau40 aggregates species, hTau40 monomer species (1 uM) alone, and along with the alpha-linolenic acid (40 uM) for 24 h at 37degC. The cells were fixed after 24 h and stained with anti-Iba-1 antibody (green) and T46 Tau antibody (red) and observed by fluorescence microscopy; scale bar is 20 um. The orthogonal images denote the internalization of Tau, indicated at X and Y plane to visualize the intracellular position. The enlarged panel indicates internalized Tau. The images were taken with the Zeiss fluorescence microscope with Apotome 2.0. (b) Quantification of mean intensity of internalized Tau in microglia cells showing the extent of internalization Tau in microglia cells, which is highly significant ( P < 0.001) compared with cell control (no treatment) and ALA-treated cells. (c) Percentage increase in phagocytosis of hTau40 in microglia after ALA exposure to cells; percentage increase in aggregates compared to aggregates with ALA-exposed groups and in monomer compared to monomer with ALA groups calculated from the intracellular intensity of Tau among the groups; significance is P = 0.02 and 0.007, respectively

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Inflammatory activation of HMC3 human microglia cell line by TNF-alpha and IFN-gamma. ( a ) Flow cytometric analyses demonstrate the increased protein expression of inflammatory microglia biomarkers (IBA-1, CD40, MHC-II, CD68, CD14, and CD86) in the HMC3 cells treated with IFN-gamma (0.3 ug/mL, 24 h) (red), but no alteration in the expression of the anti-inflammatory microglia biomarkers CD163 and CD206. TNF-alpha (0.3 ug/mL, 24 h) (blue) also increases the expression of inflammatory microglia biomarkers (IBA-1, CD40, and CD14). ( b ) q-PCR analysis revealed increased CD11b and TMEM119 expression by HMC3 microglia after addition of 0.3 ug/mL TNF-alpha or 0.3 ug/mL IFN-gamma for 24 h. Fold change is normalized to untreated control. GAPDH was used as an internal control to normalize mRNA level of the gene of measurement in each sample (n = 5 independent experiments). Quantitative analysis ( c ) and representative fluorescence micrographs ( d , displayed at x10 and x4 magnification) of the cell viability assay show that both TNF-alpha and IFN-gamma induce cell death in a concentration-dependent manner (0, 0.01, 0.03, 0.1, 0.3 ug/mL) for 24 h in the HMC3 human microglial cells. Fluorescent green features are AO stains of live cells and fluorescent red features are PI stains of dying cells. * p < 0.1, ** p < 0.01, *** p < 0.001, and NS (no significant difference).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Immunophenotype and spatial distribution of IGMs in CX3CR1 GFP mouse colon. GFP+ IGMs are present within the agrin-bordered enteric ganglia and co-express CD11b ( A-A"" ), CSF1R ( B-B"" ), F4/80 ( C-C"" ), and Iba1 ( D-D"" ). F4/80 and Iba1 are co-expressed by MMs and IGMs ( F-F"" , arrowheads , magnified from circled area in E ), but Iba1 is not present in submucosal macrophages ( F-F"" , arrows ). In lymphatic aggregates of the colonic mucosa ( E , area within dashed line ), macrophages express Iba1 but not F4/80. Comparison of MM and IGM cell number in the proximal and distal colon of CX3CR1 GFP mice shows no significant difference in ratio of IGMs to total MMs ( G ; 3.26 % +- 1.3 % vs 2.12 % +- 1.1 %, P = .0977, n = 8). However, the number of IGMs is significantly higher in distal colon compared with proximal colon when adjusted to myenteric ganglion area ( H ; 82.37 +- 32.98 vs 50.25 +- 19.6 cell/mm 2 , P = .0309, n = 8).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 DSS treatment is associated with neutrophil infiltration and increases expression of iNOS in macrophages and smooth muscle cells in a macrophage-dependent fashion. Graphs show relative RNA expression (fold change, FC) of macrophage and neutrophil markers in whole gut and isolated muscularis samples. Quantitative PCR shows significantly higher expression of neutrophil marker Ly6g in DSS-treated vs control (1.82 vs 0.66, P = .02; A ) and vs DSS+ clodronate treated (1.82 vs 0.31, P < .001; A ) mice in whole gut and DSS-treated vs control (3.47 vs 1.08, P < .001; B ) muscularis. M1-macrophage marker iNOS RNA is significantly overexpressed in DSS-treated vs control (4.24 vs 0.87, P < .001; C ) and vs DSS+ clodronate treated animals (4.24 vs 1.53, P = .045; C ) in whole gut and in muscularis (2.45 vs 0.97, P = .02, and 2.45 vs 0.78, P < .001; D ), respectively. M2-macrophage markers CD163 and ARG1 showed no significant difference ( E-H ). Immunofluorescence shows that in DSS-treated animals, Ly6G+ neutrophils are predominant in the mucosa and submucosa ( I ) but only slightly increased in the muscularis ( I', arrowheads ), where Iba1+ macrophages dominate. Ly6G expression does not co-localize with Iba1 ( I-I' ). In the mucosa, submucosa, and serosa, iNOS is expressed in F4/80+ monocytes ( J-J"", arrowheads ) and occasionally in macrophages ( J, arrow ) and F4/80- cells ( J, asterisk ). In the muscularis, F4/80+ macrophages ( K-K', arrowheads ), monocytes ( K"", arrowheads

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 Iba1 and MPO expression in DSS-treated colon. Expression of Iba1 and F4/80 is co-localized in the colon of a DSS-treated mouse ( A-C ). Expression of MPO overlaps with Ly6G in neutrophils of the mucosa and submucosa ( D ), whereas some Ly6G+ cells in the muscularis propria do not express MPO ( F-F"" ). In the serosa, ramified F4/80+ macrophages are MPO-negative ( E, arrows ), whereas round F4/80+ monocytes express MPO ( E, arrowheads ). MPO, myeloperoxidase.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Effects of young adult and elderly feces on the occurrence of cognitive impairment and colitis in the transplanted mice. Effects on the occurrence of cognitive impairment in Y-maze ( A ), NOR ( B ), and Barnes maze tasks ( C ). Effects on the BDNF + /NeuN + ( D ), NF-kappaB + /Iba1 + ( E ), and LPS + /Iba1 + cell populations ( F ) in the hippocampus. G Effects on the BDNF expression and NF-kappaB activation in the hippocampus. H Effects on the IL-1beta expression in the hippocampus, assessed by ELISA. Effects on the colon length ( I ), myeloperoxidase (MPO) activity ( J ), IL-1beta expression ( K ), NF-kappaB activation, p16 expression ( L ), and NF-kappaB + /CD11c + cell population ( M ) in the colon. Fecal transplantations of young adults (YF) and elderly people (AF) were orally gavaged once a day for 5 days. Control mice (NC) were treated with vehicle (saline) instead of fecal suspension. Data values were indicated as mean +- SD ( n = 6). Means with the same letters are not significantly different ( p < 0.05). A , B , C , I Kruskal-Wallis test with Dunn's post hoc test for non-parametric analysis. H , J , K One-way ANOVA with post hoc Bonferroni's multiple comparisons test

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Verifying the Culture of Astrocytes. ( A ) Differential Interference Contrast microscopy image showing cultured astrocytes with stellate morphology on DIV14 (scale bar: 50 mum); ( B - E ) Dual immunofluorescent image showing that most cells expressed astrocyte markers (GFAP and aldh1L1); fewer expressed Iba1 (microglia), NeuN, and MAP2 (neurons) (scale bar: 50 mum); ( F ) Among every 100 cells, 60-80 expressed astrocyte markers (aldh1L1 or GFAP), and 20 expressed neuronal cell markers (NeuN or MAP2). The remaining cells expressed a microglia marker (Iba1). (No error bar due to one cell type group each); ( G ) Triple immunofluorescent image showing that most cells expressed GFAP (astrocytes); fewer expressed MAP2 (neurons). Expression of Iba1 (microglia) was not detected (scale bar: 50 mum); ( H ) Plots analysis showing similar results to dual staining. Microglia (Iba1) was not plotted because of no detection. The graph shows that the cell culture in this study was dominated by astrocytes.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunofluorescence of a radial section of a human cochlear duct showing the distribution of IBA1 cells. In the spiral prominence, some IBA1 cells almost reach the endolymph. Scanning electron microscopy shows a free cell transitioning a cell border in the human cochlea (upper inset). Reissner's membrane (RM) may also contain macrophages (lower inset). In the SV, IBA1 cells are mostly found in the middle layer close to the blood vessels. No IBA1 cells can be observed in the organ of Corti in this section. I-IV; fibrocytes.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 (A) SR-SIM of IBA1 cells co-expressing MHCII in the human spiral ganglion. IBA1 cells mingle with Schwann cells in a peripheral axonal bundle (inset). (B) Confocal microscopy of several branched IBA1 macrophages is seen in the spiral ganglion. (C) The macrophages have nuclei expressing IBA1 protein. (D) The basal lamina surrounding the satellite cells expresses collagen IV. A macrophage (arrows) is closely related to the satellite glia cell surrounding a type I ganglion cell. The IBA1 cell is seen to cross the basal lamina.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Internalization of extracellular Tau in Microglia. a Study of internalization of extracellular Tau monomer and aggregates in the presence of ALA. The treatment was given for 24 h and studied with fluorescence microscopy to understand the internalization of Tau (red) in Iba-1 (green) positive cells. Figure showing fluorescence microscope image, single cell and enlarged panel indicates that the internalized Tau denoted with white arrow marks. The enlarged region is highlighted with white dotted square that indicates internalized area in the cells. Axio observer 7.0 Apotome 2.0 Zeiss microscope was used to the study of internalization extracellular Tau. b Quantification of internalized Tau was carried out with a total intensity of Tau (red) per mum 2 area inside the cell was analyzed by ZEN 2.3 software. The significance was analyzed with Tukey's Kramer, significant when mean difference between treatment groups (X-X') > T (Tukey's criteria). The significance of conditions of Tau monomer and aggregtes with ALA is p < 0.005. annotations used in graph are as follows- CC (Cell control), ALA (alpha-linolenic acid), Mono. (monomer), Agg. (aggregates), Mono. + ALA (monomer plus ALA), Agg. + ALA (aggregates plus ALA)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Modulation of actin network in activated microglia by ALA. Role of actin and Iba-1 in microglial migration and activation a N9 microglial cells were treated with Tau monomer, aggregates along with ALA for 24 h. After fixation cells were stained with beta-actin (red) and anti-Iba-1 antibody (green). Colocalization of actin and Iba-1 was studied by Super-resolution confocal microscopy. The single cells are marked with white dotted lines in the merged image, scale bar is 20 mum. The migratory microglia are shown with the front; leading edge and rear edge and the colocalization of actin and Iba-1 in the edges assisting the microglia for membrane ruffling and phagocytosis. b The quantification of Iba-1 in cell indicating its activation status and its levels on increased phagocytosis. The increased levels of total intensity per mum 2 area of microglia was calculated with ZEN 2.3 software, significance is ( p < 0.001). c The protein expression of Iba-1 was measured by western blot analysis in all the treated groups after 24 h of treatment and stained with anti-Iba-1 and beta-actin antibody for loading control. d Quantification of the intensity of protein bands from western blot normalized with the beta-actin loading control. The conditions of Tau monomer and aggregtes with ALA are nonsignificant, ( p > 0.05). e Schematic overview of actin remodeling at leading edge of microglia and involvement of Iba-1 in the process of phagocytosis after ALA treatment to cells. The significa

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Formation of membrane ruffles induced by ALA. Role of actin and Iba-1 in the formation of membrane ruffling was studied upon exposure of ALA. The effect of ALA in membrane ruffling was observed with the super-resolution confocal microscopy. a N9 cells were treated with Tau monomer, aggregates and ALA for 24 h followed by staining with actin and Iba-1 to study the membrane ruffling. The zoom images are indicated with the colocalization of actin and Iba-1 showing membrane ruffling in images. The sacel bar is 5 mum. b The quantification of ruffle positive cells by measuring actin foci per cell were carried out for the percentage calculation. The conditions of Tau monomer and aggregtes with ALA are significant, ( p < 0.005). The significance was analyzed with Tukey's Kramer, significant when mean difference between treatment groups (X-X') > T (Tukey's criteria). The annotations used in graph are as follows- CC (Cell control), ALA (alpha-linolenic acid), Mono. (monomer), Agg. (aggregates), Mono. + ALA (monomer plus ALA), Agg. + ALA (aggregates plus ALA)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 17-beta estradiol (ES) impedes gliosis and brain inflammation after SWI. ( a - g ) Western blot analysis showing protein expression of GFAP, Iba-1, CD64, TGF-beta, and IGF-1 in the experimental groups. Anti-beta-actin was used as a control for the protein levels across the samples. The densities are expressed in arbitrary units (AU). ( h , i ) Brain section from the experimental animals illustrating Iba-1-positive cells (red) stained with DAPI (blue) of the cortex and DG region, with the respective histogram. ( j , k ) Iba-1 immunostained sections of the cortex and hippocampal-DG region of the experimental groups with respective histograms. Values are presented as means +- S.E.M. The data presented are relative to the control group. p -value < 0.05 was considered significant. * p < 0.05 vs. control group, # p < 0.05 vs. SWI + 17-beta estradiol group. Bar = 50 mum. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Tukey's post-hoc analysis using the GraphPad Prism (ver. 8.0.2) software.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Global lack of Bim expression increased Iba1-positive cells. Wild-type and Bim -/- mice (3-month-old) underwent laser photocoagulation, and the RPE/choroid was harvested 3, 6, and 14 days later. The RPE/choroid was wholemount stained with anti-Iba1 and the positive staining area was quantified. Each point represents one laser spot. These experiments were repeated with at least 8 mice from each genotype. Scale bar = 100 um. (* p < 0.05, *** p < 0.001, **** p < 0.0001).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Mice conditionally lacking Bim expression in MPs have decreased resolution of F4/80-, CD80-, CD11b-, and Iba1-positive cells. To assess the role Bim expression plays in moderating the immune response during CNV, 3-month-old Bim Flox/Flox , Bim EC , and Bim MP mice underwent laser photocoagulation. Six days later, the RPE/choroid was wholemount stained with anti-F4/80, anti-CD80, anti-CD11b, or anti-Iba1, and the area of positive staining was quantified (on the right). Each point represents one laser spot. Experiments were performed with at least 8 mice for each condition. Scale bar = 100 um. (ns; not significant; **** p < 0.0001, *** p < 0.001, ** p < 0.01).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Microglial activation by HPU. For detection of cytokine expression, BV-2 cells were incubated for 6 h with HPU, and cultures' supernatants were collected for detection of IL-1beta panel ( A ) and TNF-alpha panel ( B ) by ELISA. The data (mean +- SEM) were analyzed by one-way parametric ANOVA with a Dunnett post-test. *** p < 0.001, **** p < 0.0001 vs. control. Panels ( C , D ): Iba1 levels in brain homogenates of HPU-treated rats were analyzed by Western blots ( C ), and quantified by densitometry ( D ). The data (mean +- SEM) were analyzed by one-way ANOVA followed by Bonferroni post hoc test. * p < 0.05, ** p < 0.01 vs. controls. All data were normalized against the endogenous actin content.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Supplementary Figure 2 Microglial recruitment through optic nerve and vein in BRAO modeling. Arrow indicated the retinal microglia. Vascular endothelial cells were stained by CD31 antibody and microglia were stained by IBA-1 antibody. Scale bars : 100 mum. BRAO, branch retinal artery occlusion. Click here for additional data file.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Obesity is associated with inflammation and blood-brain barrier alterations in the striatum. ( A ) Ventral striatal mRNA relative expression of ionized calcium-binding adapter ( Iba1 ), glial fibrillary acidic protein ( Gfap ), toll-like receptor 4 ( Tlr4 ), toll-like receptor 2 ( Tlr2 ) cluster of differenciation 45 ( Cd45 ), interleukin 6 ( Il6 ), interleukin 1 beta ( Il1b ) and tumor necrosis factor alpha ( Tnfa ) and ( B ) claudin-1 ( Cldn1 ), claudin-5 ( Cldn5 ), zonula occludens 1 ( Zo1 ), occludin ( Ocln ) and C-C chemokine ligand 2 ( Ccl2 ) measured by real-time qPCR in lean and DIO mice. ( n = 9-10/group). ( C ) Representative immunofluorescence of the dorsal striatum (D. Str), the ventral striatum (V. Str) total, core and shell and quantification of both the area occupied by astrocytes cells and the GFAP+ cells in these regions of lean and DIO mice ( n = 4-5/group). ( D ) Representative immunofluorescence of the dorsal striatum (D. Str), the ventral striatum (V. Str) total, core and shell and quantification of both the area occupied by microglial cells and the Iba1+ cells in these regions of lean and DIO mice ( n = 5/group). Data are shown as mean +- SEM. p -values were obtained after unpaired Student's t -test or non-parametric Mann-Whitney test. *: p -value < 0.05; **: p -value < 0.01; ***: p -value < 0.001 between lean vs. DIO.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Canine distemper virus (CDV) loads and distribution in the lung. ( A ) Quantification of CDV antigen at different phases of infection. Note significant increase of CDV loads in the acute (group 2) and subacute infection phase (group 3), followed by a decrease in the subacute-chronic phase (group 4). Groups: 1 = non-infected controls; 2 = acute CDV infection; 3 = subacute CDV infection; 4 = subacute-chronic CDV infection; box and whisker plots display median and quartiles with maximum and minimum values. Significant differences ( p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 TNF-alpha expression in canine distemper virus-infected lungs. ( A ) Detection of TNF-alpha in mononuclear cells by immunohistochemistry. ( B ) Double immunofluorescence labeling against TNF-alpha (green) and Iba-1 (red) confirmed histiocytic cells (arrows) as a source of TNF-alpha. Nuclei were counterstained with bisbenzimide (blue). Scale bars: 50 um.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 CX3CR1-and CX3CL1-immunohistochemistry of human spiral ganglion (A) and CD4 - , CD8 - and IBA1-immunohistochemistry of human cochlear modiolus (B and C). In A), spiral ganglion neurons (SGN) express CX3CL1 (Fractalkine) more intense in their perikaryon surface. The receptor CX3CR1-immunostaining appears diffuse in the cytoplasm of both cell bodies (MF) and processes that look like macrophages. B shows several immune cells located along the wall of scala tympani in the modiolus. Two cells positive for CD4 and CD8 respectively are magnified in B); super-resolution SIM microscopy reveals a close relation between these two cells. Fig. 3

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 SR-SIM (A,B) and confocal fluorescence microscopy (C,D) of the human ES. (A,B) show the difference in nuclear expression of IBA1 protein in macrophages (A) and fibrocytes (B) in the peri-saccular tissue. (C) The sub-epithelial tissue in the intraosseous part of the ES displays a large number of variously shaped IBA1-positive cells. In two of these cells (arrows), the typical nuclear staining can be seen. Several thin cross-sectioned ramifications of IBA1 cells are visible. (D) The epithelium also contains a large number of IBA1 cells, located both between and beneath epithelial cells (inset D' ). The epithelial cells express the chemokine fractalkine. * Shows location in the ES.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 (A) Immunofluorescence of IBA1 and collagen IV in the lateral wall of the apical turn of the human cochlea. Many perivascular IBA1 cells are seen in the StV and few in the spiral ligament. (B) Confocal microscopy of the human StV. Framed area is magnified in (C) . (C) SR-SIM of framed area in B. Cell co-express IBA1 and MHCII. The cell membrane expresses MHCII as well as cytoplasmic vesicles [ (B,C) from Kampfe-Nordstrom et al. ( 12 )]. (D) Confocal microscopy of spiral ganglion with several surrounding IBA1 cells. SGC, satellite glial cell; Nu, type I cell nucleus; Col. IV, collagen IV; cap, capillary; E, endolymph.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Actin-mediated activation of microglia by Tau oligomers. a , b N9 microglia showed an increased level of Iba1 in hTau40 WT oligomer-treated group as compared to aggregate exposure by western blot. Significant at the mean difference between treatment groups (X - X`) > Tukey's criterion (T). The # sign corresponds to non-significant by Tukey's test. c The immunostaining study revealed the accumulation of Iba1 with remodeled actin structures at the rear end of activated migratory microglia. The localization of Iba1 at the rear site of microglia may emphasize the contraction of the actin network for mediating forward movements during migration. The ""arrow"" has represented the migratory direction in front ends and the retraction of actin structures containing Iba1 from rear ends in N9 cells